Antifungal activity of 25-azalanosterol against Candida species

Eur J Clin Microbiol Infect Dis. 2008 Nov;27(11):1131-6. doi: 10.1007/s10096-008-0554-y. Epub 2008 Jun 24.

Abstract

The antifungal properties of 25-azalanosterol was investigated. Compared to normal antifungal reagents, fluoconazole, clotrimazole and voriconazole, it exhibited significant anti-Candida activity (the minimum inhibitory concentration [MIC] ranges were 0.125-8, 0.5-8 and 0.5-32 microg/mL against C. albicans, C. krusei and C. glabrata, respectively), but showed little toxicity to mice liver cells at clinical dosage after 24 h of exposure, with the lowest lactate dehydrogenase and the highest ED(50) compared to four other azoles antifungal agents. 25-Azalanosterol inhibited the incorporation of [methyl-(3)H(3)] AdoMet into the C-24 of ergosterol in whole cells of C. albicans. Thus, 25-azalanosterol, as an inhibitor of the growth of C. albicans in vitro, may have considerable potential as a new class of anti-Candida agent that lacks toxic side effects in the mammalian host.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / toxicity
  • Candida / drug effects*
  • Cell Line
  • Hepatocytes / drug effects
  • Humans
  • Inhibitory Concentration 50
  • Lanosterol / analogs & derivatives*
  • Lanosterol / pharmacology*
  • Lanosterol / toxicity
  • Mice
  • Microbial Sensitivity Tests
  • S-Adenosylmethionine / antagonists & inhibitors

Substances

  • Antifungal Agents
  • Lanosterol
  • S-Adenosylmethionine